ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Archives for May 2024

Mounting Evidence Supporting Neoadjuvant ChemoIO Means Surgeons Must Adapt

Ke-Neng Chen, MD
on: May 21, 2024In: Evolving Standards of Care
Mounting Evidence Supporting Neoadjuvant ChemoIO Means Surgeons Must Adapt

In a two-part commentary, Dr. Ke-Neng Chen discusses how surgeons must adjust in light of recent clinical trials, beginning with a discussion of the challenges of TNM staging. Read more


More Than Ever, Surgeons Must Collaborate to Ensure Patients Receive Appropriate Care

Ke-Neng Chen, MD
on: May 21, 2024In: Evolving Standards of Care
More Than Ever, Surgeons Must Collaborate to Ensure Patients Receive Appropriate Care

As thoracic surgery in the management of NSCLC evolves, Dr. Ke-Neng Chen highlights the importance of avoiding unnecessary treatments and using a multidisciplinary approach. Read more

A New Treatment Option for Early-Stage ALK+ NSCLC: Adjuvant Alectinib

Narjust Florez, MD
on: May 21, 2024In: Evolving Standards of Care
A New Treatment Option for Early-Stage ALK+ NSCLC: Adjuvant Alectinib

In part 2 of their interview, Drs. Narjust Florez and Benjamin Solomon dig deeper into the implications of the ALINA trial, discussing endpoints, toxicities, and future directions. Read more

European Commission OKs Tislelizumab for NSCLC

Erin Jungmeyer
on: May 21, 2024In: Industry News & Regulatory Approvals
European Commission OKs Tislelizumab for NSCLC

In other regulatory news, the US FDA recently granted a Breakthrough Therapy Designation for sunvozertinib for first-line treatment of advanced non-small cell lung cancer with EGFR Exon 20 Insertion mutations. Read more

In Case You Missed It: Recent News from IASLC

Erin Jungmeyer
on: May 21, 2024In: Society News
In Case You Missed It: Recent News from IASLC

Submit abstracts for ACLC 2024 by June 7, register for the 2024 CT Screening Symposium, and contribute memories for the 50th anniversary time capsule. Read more

Increased Biomarker Uptake Needed to Further Realize Potential of Precision Medicine

Christian Rolfo, MD, PhD, MBA, Drhc
+more
on: May 07, 2024In: Evolving Standards of Care
Increased Biomarker Uptake Needed to Further Realize Potential of Precision Medicine

Drs. Christian Rolfo and Valeria Denninghoff contend that data show improvements in outcomes from personalized treatment may have stalled and that increased testing for driver genes alterations is needed. Read more

Adjuvant Alectinib for ALK+ NSCLC: An Interview with Dr. Benjamin Solomon

Narjust Florez, MD
on: May 07, 2024In: Early Stage
Adjuvant Alectinib for ALK+ NSCLC: An Interview with Dr. Benjamin Solomon

Speaking with Dr. Narjust Florez, Prof. Solomon discusses the design and results of the ALINA trial. Read more

ALINA Trial Leads to New Treatment Option for Early-Stage ALK+ NSCLC

Erin Jungmeyer
on: May 07, 2024In: Industry News & Regulatory Approvals
ALINA Trial Leads to New Treatment Option for Early-Stage ALK+ NSCLC

The US approved alectinib as adjuvant treatment based on a significant DFS benefit compared to chemotherapy. Read more

Could Precision Oncology Evolve to Treat Cancer Before It Develops?

Laila C. Roisman, PhD
+more
on: May 07, 2024In: Evolving Standards of Care
Could Precision Oncology Evolve to Treat Cancer Before It Develops?

Drs. Laila Roisman and Nir Peled envision a future where artificial intelligence elevates personalized medicine in ways once thought impossible. Read more

Stark Contrast in Recent Tobacco Control Laws Worldwide

Erin Jungmeyer
on: May 07, 2024In: Industry News & Regulatory Approvals, Tobacco Control & Smoking Cessation
Stark Contrast in Recent Tobacco Control Laws Worldwide

The UK recently moved to ban smoking for individuals born after 2009 while the US delayed implementation of a ban on menthol cigarettes—again. Read more

SEARCH ILCN

Archives

PROVIDER RESOURCES

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED


COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy